AOD-9604 vs HGH Fragment 177-191: Key Differences in Research Settings | Palmetto Peptides

AOD-9604 vs HGH Fragment 177-191: Key Differences in Research Settings | Palmetto Peptides AOD-9604 and HGH examined side-by-side in research. Covers mechanisms, receptor activity, lab study findings, and key differences Explore the research. Research Notice: This article covers research on AOD-9604 research peptide and Tesamorelin research peptide — available from Palmetto Peptides for laboratory use only. Research Use Only Disclaimer: All peptides listed on this page are sold exclusively for in vitro and legitimate laboratory research purposes. They are not intended for human consumption, veterinary use, or any clinical application. The information in this article is for scientific and educational reference only and does not constitute medical advice. All research use must comply with applicable federal, state, and institutional regulations. Palmetto Peptides complies fully with all applicable FDA guidelines. Research Disclaimer: AOD-9604 and HGH fragment 177-191 are research compounds not approved by the FDA for human or veterinary use. This comparison is provided for scientific and educational purposes only and does not constitute medical advice. For researchers navigating the literature on growth hormone-derived peptide fragments, one of the most common points of confusion is the relationship between AOD-9604 and the native HGH fragment 177-191. They share a core sequence, they are derived from the same region of human growth hormone, and they are often discussed in overlapping contexts. However, they are structurally distinct compounds that behave differently in certain research applications. This article breaks down those differences clearly. Last Updated: April 6, 2026 | Reading Time: Approximately 8 minutes | Author: Palmetto Peptides Research Team For researchers navigating the literature on growth hormone-derived peptide fragments, one of the most common points of confusion is the relationship between AOD-9604 and the native HGH fragment 177-191. They share a core sequence, they are derived from the same region of human growth hormone, and they are often discussed in overlapping contexts. Both compounds are derived from the C-terminal region of human growth hormone (hGH). The relevant portion of the hGH sequence spans positions 177 through 191, a 15-residue segment that includes two cysteine residues forming a disulfide bridge. This shared sequence is what makes the two compounds closely related. The native HGH fragment 177-191 is simply this 15-residue segment in its unmodified form. AOD-9604, on the other hand, is a modified version: the same 15-residue sequence with an additional tyrosine (Tyr) residue added to the N-terminus, making it a 16-residue peptide officially designated Tyr-hGH177-191. Residue count 16 amino acids 15 amino acids N-terminal modification Tyrosine added None (Leu is N-terminal) Molecular formula C₇₈H₁₂₃N₂₃O₂₃S₂ ~C₇₁H₁₁₄N₂₂O₂₀S₂ Molecular weight ~1817 g/mol ~1636 g/mol Disulfide bond Present (Cys⁷-Cys¹⁴ within the sequence) Present (Cys⁶-Cys¹³ within the sequence) Radiolabeling capability Yes (¹²⁵I via Tyr hydroxyl group) Limited without modification Research availability Widely available; large published literature base Less common; smaller literature base Primary research designation AOD-9604, Tyr-hGH177-191 HGH 177-191, hGH(177-191) CAS Number 221231-10-3 Not widely standardized The decision to add a tyrosine residue at the N-terminus of hGH 177-191 was a deliberate research engineering choice, not an accident. The primary reasons are discussed in detail in our article on [History and Laboratory Synthesis of AOD-9604 from hGH Fragments], but the key points are: Radioiodination. Tyrosine's aromatic phenolic hydroxyl group reacts readily with radioactive iodine (¹²⁵I) under standard laboratory conditions. This allows researchers to produce radiolabeled AOD-9604 for use in receptor binding assays, autoradiography studies, and pharmacokinetic tracer experiments. The native 177-191 fragment, which begins with leucine at its N-terminus, does not offer this convenient labeling site. Research standardization. The addition of tyrosine became part of the compound's identity from early development, meaning that virtually all published research on this hGH-derived fragment has used the tyrosine-modified form. This creates a consistent research reference point across studies. Potential conformational influence. The aromatic side chain of tyrosine at the N-terminus may contribute to the peptide's three-dimensional shape and solubility behavior, though the precise functional significance of this modification in different experimental systems has been a subject of investigation rather than settled science. In studies designed to characterize receptor or binding protein interactions, AOD-9604 holds a clear practical advantage over the native 177-191 fragment. The tyrosine modification enables straightforward radioiodination, making AOD-9604 the preferred choice for radioligand binding work. Researchers using ¹²⁵I-labeled AOD-9604 can quantify binding affinity, measure receptor occupancy, and conduct competitive displacement assays with precision. The native fragment, without a convenient labeling site, would require additional chemical modification (such as introducing a different reactive group) before it could be used in standard radioligand protocols, adding synthesis complexity and potential structural perturbation. In cell-based assays examining effects on adipocyte cultures or other relevant cell types, the two compounds may produce somewhat different results due to the structural difference at the N-terminus. The tyrosine residue could influence the compound's interaction with cell surface molecules, its rate of uptake, or its stability in cell culture media. Researchers designing comparative in vitro studies should treat AOD-9604 and the native 177-191 fragment as distinct experimental variables and include appropriate controls when comparing results across the two compounds. Both compounds contain a disulfide bond and share similar considerations for reconstitution and storage. Reducing environments (such as buffer systems containing dithiothreitol or beta-mercaptoethanol) should be avoided for both, as they can disrupt the critical intramolecular disulfide bridge. For detailed guidance on handling either compound, see our articles on [Step-by-Step Reconstitution Protocols for AOD-9604 in Laboratory Research] and [Storage Stability and Shelf Life Guidelines for AOD-9604 Research Vials]. A related but different compound that appears in some research literature is the HGH fragment 176-191, which includes one additional amino acid (leucine at position 176) at the N-terminus compared to the 177-191 fragment. This compound is distinct from both AOD-9604 and the native 177-191 fragment and should not be treated as interchangeable in research protocols. The existence of 176-191 in the literature adds to the potential for confusion when reading published studies, particularly older papers where the naming conventions were less standardized. Researchers should always verify the exact sequence and residue count of any compound referenced in a study before drawing comparisons or designing follow-on experiments. The answer depends on the type of study being designed: Choose AOD-9604 when: - Radioiodination for binding studies is part of the protocol - You want access to the largest published literature base for comparison - Your study is based on previous AOD-9604 preclinical or in vitro research - Supplier availability and certificate of analysis documentation are priorities Consider the native 177-191 fragment when: - Your study specifically aims to compare the modified versus unmodified form - The N-terminal tyrosine is a confounding variable for the question you are investigating - Your lab has in-house synthesis capability and can verify the compound identity independently For most research contexts, AOD-9604 is the de facto standard compound when studying this region of hGH. The native fragment sees more use in specialized mechanistic or structural comparison studies.